Published in BMC Med Inform Decis Mak on June 17, 2010
Providing care for cancer survivors in integrated health care delivery systems: practices, challenges, and research opportunities. J Oncol Pract (2012) 1.31
The role of informatics in promoting patient-centered care. Cancer J (2011) 0.96
A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials (2014) 0.90
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience (2016) 0.88
Empowerment of Cancer Survivors Through Information Technology: An Integrative Review. J Med Internet Res (2015) 0.85
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public? Urol Oncol (2010) 0.83
Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. Trials (2012) 0.80
Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment. BMC Med Inform Decis Mak (2011) 0.80
Health information needs and preferences in relation to survivorship care plans of long-term cancer survivors in the American Cancer Society's Study of Cancer Survivors-I. J Cancer Surviv (2016) 0.78
E-mail communication in pain practice: The importance of being earnest. Saudi J Anaesth (2014) 0.76
Downregulated miR-495 [Corrected] Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer. Medicine (Baltimore) (2015) 0.76
It's a long shot, but it just might work! Perspectives on the future of medicine. BMC Med (2016) 0.75
The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology (1997) 13.27
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 6.42
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Patients' experience with a diabetes support programme based on an interactive electronic medical record: qualitative study. BMJ (2004) 3.44
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol (1998) 2.03
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc (2007) 1.89
Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol (2009) 1.72
Randomized controlled trial of an internet-based versus face-to-face dyspnea self-management program for patients with chronic obstructive pulmonary disease: pilot study. J Med Internet Res (2008) 1.61
Noncompliance with vision care guidelines in Latinos with type 2 diabetes mellitus: the Los Angeles Latino Eye Study. Ophthalmology (2006) 1.33
Acceptability of an Electronic Self-Report Assessment Program for patients with cancer. Comput Inform Nurs (2008) 1.29
Electronic Self-report Assessment--Cancer (ESRA-C): Working towards an integrated survey system. Stud Health Technol Inform (2006) 1.15
Internet-based self-management offers an opportunity to achieve better asthma control in adolescents. Chest (2007) 1.11
Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis. Health Technol Assess (2004) 1.11
A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. Clin Prostate Cancer (2005) 1.04
Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer (2008) 1.04
Comparison of 3 data collection methods for gathering sensitive and less sensitive information. Ambul Pediatr (2008) 1.04
Web-based or paper-based self-management tools for asthma--patients' opinions and quality of data in a randomized crossover study. Stud Health Technol Inform (2007) 0.99
Routine symptom assessment: good for practice and good for business. Support Care Cancer (2008) 0.97
Perceptions in 7700 patients with rheumatoid arthritis compared to their families and physicians. Joint Bone Spine (2007) 0.94
Developing a shared electronic health record for patients and clinicians. Stud Health Technol Inform (2008) 0.92
A retrospective study on the use of post-operative colonoscopy following potentially curative surgery for colorectal cancer in a Canadian province. BMC Cancer (2004) 0.91
Does management of erectile dysfunction after radical prostatectomy meet patients' expectations? Results of a national survey (REPAIR) by the French Urological Association. J Sex Med (2008) 0.89
Measuring the severity of upper gastrointestinal complaints: does GP assessment correspond with patients' self-assessment? Fam Pract (2007) 0.88
Help me help you: support groups in cancer therapy. Oncologist (2004) 0.81
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med (2007) 4.68
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med (2012) 4.18
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Against diagnosis. Ann Intern Med (2008) 3.69
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet (2006) 3.23
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol (2010) 2.61
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials (2010) 2.54
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Nocturia and quality of life: results from the Boston area community health survey. Eur Urol (2011) 2.34
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol (2012) 2.15
Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause (2006) 2.12
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Therapeutic applications of fenugreek. Altern Med Rev (2003) 2.12
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology (2011) 2.10
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ (2004) 2.03